Biomedical subjects
Publications and source records attributed to J S Tan.
An 86-year-old woman developed large bullae on both legs during the course of septicemia due to Yersinia enterocolitica. Although erysipelas-like lesions and erythema nodosum have been known to be associated with Yersinia infections, this is the first reported case with multiple bullae.
The approach to management of patients with presumed infection in the nursing home is influenced by the limited availability of diagnostic tests and support staff. Although antibiotics are most often prescribed in the absence of laboratory data, many studies indicate that empirical therapy for nursing home infections is relatively successful. With the scrutiny on containment of healthcare costs, therapy of nursing home patients has been changing and will continue to shift toward treatment within nursing homes without transfer to a hospital. Better oral antimicrobial agents with a wide spectrum of activity, such as the fluoroquinolones, will play a major role in the treatment of many infections acquired in the nursing home. Because of the favourable characteristics of the fluoroquinolone agents, they should be useful for elderly patients who develop infections in nursing homes. They have excellent in vitro activity against Gram-negative bacteria which are often multidrug-resistant and are common in nursing home patients. Studies indicate that absorption of orally administered fluoroquinolones is very efficient in the elderly and these drugs are well tolerated. Numerous clinical trials have documented good efficacy of the fluoroquinolones in the treatment of elderly patients for the most common infections in the nursing home, including urinary tract infections, respiratory tract infections and skin infections.
The experience at CIGNA Healthplans shows that a quality assurance program can be instituted in an IPA-model HMO at low cost and with the addition of little new staff. Existing resources can be effectively restructured to implement a functional program of a traditional type that is easily understood by employer groups, members, and providers. It can serve as a transitional process until the HMO is large enough to put a total quality management program in place.
The 'atypical' pathogens are important causes of pneumonia, causing illness ranging from mild to life-threatening. The most common atypical pathogens are Mycoplasma pneumoniae and Chlamydia pneumoniae; others include Legionella species, Chlamydia psittaci and viruses such as influenza, adenovirus and respiratory syncytial virus. Infection rates for these agents are difficult to determine because many clinicians and investigators do not routinely test for them, but reported rates are in the range of up to 8% (for C pneumoniae) and 15% to 20% (M pneumoniae) of all cases of pneumonia. Diagnostic testing is very difficult because most of these agents cannot be easily cultured. Diagnosis relies on either high acute antibody titres (quickly available but not very accurate) or paired serology samples (more accurate but requires at least a week). While rapid identification using automated polymerase chain reaction testing may be possible in the future, current management is based largely on empirical treatment.
The 185 hospitalized patients (aged 19 to 95 years) with pneumonia were randomly assigned to receive 500 mg of cefuroxime axetil orally (250 mg q12h), 1,000 mg of cefuroxime axetil orally (500 mg q12h), or 1,500 mg of cefaclor orally (500 mg q8h), daily, for a mean of nine days. Among the 151 evaluable patients, clinical cure was noted in 58% of the 500-mg cefuroxime axetil group, 94% of the 1,000-mg cefuroxime axetil group, and 88% of the cefaclor group, and clinical improvement in 32%, 4%, and 9%. Bacteriologic outcome was similar in the three groups. Adverse events were minor and comparable among the treatment groups. Cefuroxime axetil is a safe and effective oral antimicrobial for the treatment of pneumonia in adults.
Foot infections are common in the diabetic patient. They result from a interplay of neuropathy, ischemia, and metabolic alterations. The team approach in the management of diabetic foot infections can provide the most optimal and probably the most cost-effective care. The cornerstone of treatment is early recognition and prompt intervention. After diagnostic cultures are obtained, infections should be treated with appropriate antibiotics. Bony deformities should be corrected. The vascular status of the patient should be evaluated, and if necessary, treatment should be directed at improving blood flow to the affected foot.
Explore the source record for details and available documents.